Anti-FLT
The present invention provides novel human fins related tyrosine kinase 3 (FLT 3 ) antigen binding proteins, such as antibodies, having improved FLT 3 binding affinity, and/or anti-tumor activity. The FLT 3 antibodies of the invention were generated by mutation of a parent FLT 3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT 3 ×CD 3 antibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT 3 antigen binding protein (ABP) of the invention.
1. An Antigen Binding Protein (ABP), wherein the ABP comprises two antibody heavy chain sequences, and two antibody light chain sequences, wherein said antibody heavy chain sequences comprise the amino acid sequence of SEQ ID NO: 21 and the antibody light chain sequences comprise the amino acid sequence of SEQ ID NO: 22.
2. The ABP according to claim 1 , wherein the ABP is labelled.
3. The ABP according to claim 1 , wherein the ABP is a monoclonal antibody, a fragment of an antibody, or a fragment of a monoclonal antibody.
4. The ABP according to claim 3 , wherein said antibody is an IgG, IgE, IgD, IgA, or IgM immunoglobulin.
5. The ABP according to claim 3 , which is F(ab′)2 antibody fragment.
6. The ABP according to claim 1 , wherein said ABP is modified or engineered to increase antibody-dependent cellular cytotoxicity (ADCC), or wherein said ABP is afucosylated.
7. An Antigen Binding Protein (ABP), wherein the ABP is bispecific, comprising
a. an FLT-3 antigen binding domain comprising two antibody heavy chain sequences and two antibody light chain sequences, wherein said antibody heavy chain sequences comprise the amino acid sequence of SEQ ID NO: 34 and the antibody light chain sequences comprise the amino acid sequence of SEQ ID NO: 35, and
b. a second antigen binding domain.
8. The ABP of claim 7 , wherein the second antigen binding domain comprises an UCHT1 anti-CD3 scFv comprising the amino acid sequence of SEQ ID NO: 14.
9. An isolated nucleic acid comprising a sequence encoding for the ABP of claim 1 .
10. A nucleic acid construct (NAC) comprising the nucleic acid of claim 9 and one or more additional sequence features permitting the expression of the ABP in a cell.
11. A recombinant host cell comprising the nucleic acid of claim 9 .